Franklin Resources’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,161,382
| Closed | -$3.53M | – | 3102 |
|
|
2024
Q4 | $3.53M | Sell |
1,161,382
-3,623,276
| -76% | -$15.8M | ﹤0.01% | 1504 |
|
|
2024
Q3 | $24.6M | Sell |
4,784,658
-1,474,260
| -24% | -$7.33M | 0.01% | 826 |
|
|
2024
Q2 | $16.1M | Sell |
6,258,918
-24,489
| -0.4% | -$83.6K | ﹤0.01% | 931 |
|
|
2024
Q1 | $30.9M | Buy |
6,283,407
+1,533,868
| +32% | +$9.08M | 0.01% | 729 |
|
|
2023
Q4 | $41.7M | Buy |
4,749,539
+711,978
| +18% | +$5.83M | 0.02% | 558 |
|
|
2023
Q3 | $46.3M | Buy |
4,037,561
+1,775,082
| +78% | +$34.1M | 0.02% | 514 |
|
|
2023
Q2 | $57.3M | Sell |
2,262,479
-12,012
| -0.5% | -$374K | 0.03% | 484 |
|
|
2023
Q1 | $73.3M | Sell |
2,274,491
-110,099
| -5% | -$3.43M | 0.04% | 428 |
|
|
2022
Q4 | $44M | Sell |
2,384,590
-1,428
| -0.1% | -$32.7K | 0.02% | 563 |
|
|
2022
Q3 | $64.4M | Buy |
2,386,018
+19,651
| +0.8% | +$399K | 0.04% | 464 |
|
|
2022
Q2 | $32.7M | Buy |
2,366,367
+153,320
| +7% | +$2.36M | 0.02% | 669 |
|
|
2022
Q1 | $43.2M | Buy |
2,213,047
+392,978
| +22% | +$5.96M | 0.02% | 636 |
|
|
2021
Q4 | $29.7M | Sell |
1,820,069
-1,610
| -0.1% | -$26.8K | 0.01% | 786 |
|
|
2021
Q3 | $50.8M | Sell |
1,821,679
-4,088
| -0.2% | -$117K | 0.02% | 655 |
|
|
2021
Q2 | $54.1M | Buy |
1,825,767
+69,157
| +4% | +$1.99M | 0.02% | 623 |
|
|
2021
Q1 | $49.1M | Buy |
1,756,610
+747
| +0% | +$20.7K | 0.02% | 623 |
|
|
2020
Q4 | $49.8M | Sell |
1,755,863
-822,170
| -32% | -$21.3M | 0.02% | 596 |
|
|
2020
Q3 | $64.8M | Sell |
2,578,033
-888,855
| -26% | -$23.3M | 0.03% | 485 |
|
|
2020
Q2 | $83.3M | Sell |
3,466,888
-224,600
| -6% | -$4.43M | 0.04% | 424 |
|
|
2020
Q1 | $54.6M | Buy |
3,691,488
+108,516
| +3% | +$2.24M | 0.04% | 443 |
|
|
2019
Q4 | $58.2M | Buy |
3,582,972
+16,397
| +0.5% | +$254K | 0.03% | 514 |
|
|
2019
Q3 | $46.4M | Buy |
3,566,575
+52,525
| +1% | +$643K | 0.03% | 550 |
|
|
2019
Q2 | $45.6M | Buy |
3,514,050
+84,794
| +2% | +$1.07M | 0.02% | 572 |
|
|
2019
Q1 | $54M | Buy |
3,429,256
+453,412
| +15% | +$7.86M | 0.03% | 508 |
|
|
2018
Q4 | $59.9M | Buy |
2,975,844
+426,109
| +17% | +$9.39M | 0.04% | 452 |
|
|
2018
Q3 | $63.4M | Sell |
2,549,735
-104,701
| -4% | -$2.85M | 0.03% | 480 |
|
|
2018
Q2 | $72.9M | Sell |
2,654,436
-518,726
| -16% | -$15.6M | 0.04% | 439 |
|
|
2018
Q1 | $97.7M | Sell |
3,173,162
-221,040
| -7% | -$7.11M | 0.05% | 365 |
|
|
2017
Q4 | $121M | Buy |
3,394,202
+105,424
| +3% | +$3.03M | 0.06% | 322 |
|
|
2017
Q3 | $90.6M | Sell |
3,288,778
-86,460
| -3% | -$2.1M | 0.04% | 388 |
|
|
2017
Q2 | $89.1M | Buy |
3,375,238
+391,638
| +13% | +$8.73M | 0.04% | 391 |
|
|
2017
Q1 | $62.1M | Sell |
2,983,600
-296,984
| -9% | -$6.1M | 0.03% | 468 |
|
|
2016
Q4 | $67.9M | Buy |
3,280,584
+173,305
| +6% | +$2.9M | 0.04% | 440 |
|
|
2016
Q3 | $50.4M | Sell |
3,107,279
-59,257
| -2% | -$860K | 0.03% | 520 |
|
|
2016
Q2 | $43.1M | Sell |
3,166,536
-162,534
| -5% | -$2.87M | 0.02% | 570 |
|
|
2016
Q1 | $58.1M | Buy |
3,329,070
+150,175
| +5% | +$3.06M | 0.03% | 497 |
|
|
2015
Q4 | $109M | Sell |
3,178,895
-65,385
| -2% | -$2.27M | 0.06% | 339 |
|
|
2015
Q3 | $96.5M | Buy |
3,244,280
+177,393
| +6% | +$5.39M | 0.05% | 356 |
|
|
2015
Q2 | $98.1M | Sell |
3,066,887
-331,305
| -10% | -$8.52M | 0.04% | 397 |
|
|
2015
Q1 | $70.4M | Buy |
3,398,192
+644,053
| +23% | +$11.1M | 0.03% | 492 |
|
|
2014
Q4 | $46.7M | Buy |
2,754,139
+1,367,240
| +99% | +$23.9M | 0.02% | 617 |
|
|
2014
Q3 | $26.8M | Buy |
1,386,899
+1,040,236
| +300% | +$27.1M | 0.01% | 782 |
|
|
2014
Q2 | $11.8M | Buy |
+346,663
| New | +$10.9M | 0.01% | 1030 |
|
Other funds holding RVNC
Franklin Resources's RVNC Position: Q1 2025 in Review
Franklin Resources sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,161,382 shares — an estimated $3.53M sold.
Franklin Resources first reported a position in RVNC in Q2 2014 and held it in 43 quarters. The position peaked at $121M in Q4 2017. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Franklin Resources reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Franklin Resources sold 1,161,382 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $3.53M.
- Franklin Resources first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 43 quarters.
- Franklin Resources's Revance Therapeutics, Inc. position peaked at $121M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Franklin Resources's 13F filing for Q1 2025, filed 13 May 2025.